AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world.

ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Their mission is to help overcome challenges with innovative tools and solutions from discovery to the clinic. They supply life science tools designed to be used in discovery research and scalable to the clinical phase and beyond. By consistently adapting to new regulatory challenges and guidelines, they deliver solutions, whether it comes through recombinant proteins, antibodies, assay kits, GMP-grade reagents, or custom services. They empower scientists and engineers dedicated towards innovation to simplify and accelerate the development of new, better, and more affordable medicine. ACROBiosystems way of addressing challenges in biologics development is to offer a comprehensive array of tools and solutions designed for each development phase. Starting from discovery and development and moving beyond commercialization, they strive to deliver high quality solutions that support each step of the development process. This means bringing together innovation and technology through product development and collaborations to help their customers achieve results that are translatable into the clinic and beyond.

Actome GmbH, a high-potential startup recognized by the European Innovation Council (EIC), is advancing protein analysis. Based in Freiburg, Actome has developed an innovative method called PICO (Protein Interaction Coupling) Technology, which allows scientists worldwide to analyze and quantify proteins, protein-protein interactions, and post-translational modifications with high throughput. This advanced technology significantly enhances research efficiency. Imagine completing 96 Western Blots or Co-Immunoprecipitations in just one day—transforming the pace of scientific discovery. Recently, Actome has expanded its product portfolio to include advanced tools for the quantification and characterization of extracellular vesicles. With the financial support of the EIC, Actome is now developing a method for the absolute quantification of proteins in single cells, pushing the boundaries of cellular analysis.

Aomics GmbH is spearheading a revolution in healthcare through cutting-edge immuno-oncology research. As a company centered on immuno-informatics and clinical data science, they offer extensive services in statistical consulting, statistical programming, and bioinformatics, specifically tailored for healthcare initiatives. Aomics’ expertise is particularly concentrated in the domain of Immuno-Oncology research studies.

Structural biology is a powerful enabler in areas such as drug development, protein engineering, or understanding of structure-function relationships in protein sciences. Companies often lack the capacity to perform or interpret structural biology studies, which require highly specialized equipment, trained personnel, and a good understanding of the involved sciences. At BIMOVIS, our mission is to empower life science businesses by providing easy access to structural biology. We offer tailored services, partnerships, and trainings, not only in structural biology but also in molecular visualization. We believe that this unique combination opens new routes in protein sciences and structure-based drug design, and fosters engagement of non-science stakeholders. Through individual consultations and professional project management our expert team guides each client through scientific collaboration. Our core services are: • Experimental structure determination (X-ray crystallography and cryo-EM, including gene-to-structure services) • Computational analysis (protein engineering, structure interpretation) • High-end molecule visualization for communication & marketing (2D graphics, 3D animations, 3D models and print-outs) BIMOVIS is part of Heidelberg’s innovative BioLabs, member of the BioRN cluster, and partners with world-class scientific institutions in the region to provide the best solutions and networks for our clients.

Collaborative Drug Discovery (CDD) bietet eine schnell einsetzbare, intuitive Cheminformatics-Software-Suite für Biologen und Chemiker in akademischen, biotechnologischen und pharmazeutischen Einrichtungen. Das Flaggschiff-Produkt, CDD Vault, ermöglicht es Forschern, biologische und chemische Daten zu organisieren und zu analysieren sowie über eine Web-Schnittstelle mit Partnern zusammenzuarbeiten. CDD Vault unterstützt Wissenschaftler dabei, Entitäten zu registrieren, Inventar zu verfolgen, Bioassay-Daten zu verwalten, Experimente zu erfassen, Struktur-Aktivitäts-Beziehungen (SAR) zu berechnen und ihre Daten nach Arzneimittelkandidaten zu durchsuchen. Es fungiert auch als elektronisches Laborbuch (ELN), um experimentelle Ergebnisse zu erfassen und zu teilen. CDD Vault zeichnet sich durch ein intuitives Design, überlegene Leistung und Arbeitsabläufe für sicheres, kollaboratives Daten-Sharing aus. CDD wurde 2004 gegründet und dient heute Tausenden von Forschern weltweit, die sich mit Arzneimittelentwicklung beschäftigen. Erfahren Sie mehr unter www.collaborativedrug.com.

Croda Pharma is a leading partner for the development of excipients and the supply of high purity materials for pharmaceutical formulations. The company is focused on empowering biologics drug delivery, through its adjuvant systems, small molecule, protein, and nucleic acid delivery platforms. With a wide range of solutions for both human and animal health markets, the pharmaceutical portfolio is unsurpassed in its excellence. Croda Pharma’s products, along with its in-house formulation and regulatory expertise, allows the company to meet its customers’ most demanding formulation needs. The company is committed to enabling the next generation of drug delivery systems.

​Enamine has established a new site located in Frankfurt am Main, Germany. Enamine is a leading provider of high-quality products and services for Drug Discovery. Enamine Germany will expand Enamine’s reach in Europe and provide local access to its renowned services. Enamine globally provides Screening Compounds, Building Blocks, and Fragments for supporting a wide range of research programs conducted by Pharmaceutical and Biotech companies, Drug Discovery Centers, Academic Institutions, and other research organizations worldwide. At Enamine Germany we have an international team of scientists experienced in different chemical disciplines. We offer cutting-edge chemistry support to any life science-related projects including synthesis of sophisticated individual compounds and unchallenged parallel synthesis of small, focused libraries besides conventional wet chemistry. Our high-level scientists become your fully dedicated collaborators and sparring partners to tackle challenging projects. Our partnership offers direct interaction with our chemists, always securing the highest level of confidentiality. We offer FTE chemistry support, Custom Synthesis, Medicinal Chemistry Support, including Hit-to-Lead, SAR, Route Scouting and much more to support each aspect of the early drug discovery process.

ERBC Group: We choose the right options for your product, early. More than a leading independent non-clinical CRO (Contract Research Organization), ERBC Group enables the evaluation of drug candidates on behalf of the pharmaceutical industry and biotechnology companies, providing all services from preclinical proof-of-concept to market. Chemicals, medical devices, cosmetics are also products that we can help you develop with a full suite of innovative models and translational services. With a family size group of >400 employees, ERBC offers a connected and agile environment of translational solutions and models to bridge the gap between preclinical and clinical research by better predicting the efficacy and safety of new compounds. As a leading player delivering GLP services with AAALAC high-quality standards, ERBC Group actively contributes to the development of innovative therapies in various field of research such as oncology and immuno-oncology, neurodegenerative studies, infectious diseases. Why you should choose ERBC? Team of experts and alliance managers to guide you through the strategic choice of the right translational models and services Broad range of discovery capabilities including short term and cost-effective translational approaches Innovative technologies: 3D imaging platform, BSL2/3, Digital-PCR, large-scale analysis Translational models from in vitro, through embryo innovative PDX to GEM and humanized models Personalized medicine and patient stratification at discovery stages Competitive turn-around time to start your studies

FGK, an owner-driven Clinical Research Organization, provides full service for clinical studies to biotechnology, medical device and pharmaceutical companies. FGK has the right size to handle international multi-center studies with hundreds of patients or single country studies with a few patients, but is still small enough to guarantee a personal service to the sponsor. Founded in Munich in 2002, we now have 240 highly qualified medical, scientific and regulatory experts in the EU and the UK with all knowledge and experience necessary to succeed in Europe. We can provide full service or only partial support from study start-up to final report (for a full list of services see fgk-cro.com).

The German Cancer Research Center (DKFZ) is one of the world’s leading cancer research centers, located in Heidelberg, Germany, with more than 3,000 employees. The center’s research focuses on all aspects of cancer such as the biology of cancer cells, tumor immunology, cancer genetics, epigenetics, and cancer epidemiology. The Innovation Management department is responsible for identifying, developing, and commercializing innovative technologies and products arising from this research. With the primary goal to bridge the gap between basic research and practical applications, the Innovation Management team works closely with scientists, clinicians, and industry partners to identify promising research results and develop them into market-ready solutions. This includes patenting, licensing, and spin-off creation, as well as establishing collaborations and partnerships to advance the translation of research findings into clinical practice. By doing so, DKFZ Innovation Management is continuously aiming to foster the development of new cancer therapies, diagnostic tools, and personalized medicine approaches that benefit patients and the medical community.

Gyros Protein Technologies provides enabling peptide synthesis and bioanalytical solutions helping scientists increase biomolecule performance and productivity in pre-clinical/clinical development and bioprocess applications. The automated Gyrolab® immunoassay platforms and expanding portfolio of kits are used by scientists in leading pharmaceutical, biotech and CRO/CMO companies in the development and manufacturing of biotherapies including cell and gene therapies. Gyrolab immunoassays provide key workflow advantages of speed, automation, and low sample and reagent usage with a wide dynamic range in applications including PK/PD, immunogenicity, titer determination, and analysis of bioprocess-related impurities. Gyros Protein Technologies is a division of Mesa Laboratories.

Heidelberg Pharma works on a new treatment approach in oncology and develops novel drugs based on its ADC technologies. ADCs are antibody-drug conjugates that combine the specificity of antibodies with the efficacy of toxins: Selected antibodies are loaded with cytotoxic compounds that are transported into diseased cells, where the toxins then unleash their effect and kill the diseased cells. The company uses several compounds and has built up an ADC toolbox that overcomes tumor resistance and addresses different types of cancer using various antibodies. Heidelberg Pharma is the first company to use the compound Amanitin in cancer therapy. The biological mechanism of action of the toxin from the death cap mushroom represents a new therapeutic modality. It offers the opportunity to break through therapy resistance and also eliminate dormant tumor cells, which could lead to significant progress in cancer therapy – even for patients who no longer respond to other treatment. The Amanitin-based ADC development candidates are called ATACs. The most advanced product candidate HDP-101 is a BCMA-ATAC for the indication multiple myeloma, which is currently in clinical development. The first candidate that Heidelberg Pharma is developing with a toxin other than Amanitin is HDP-201, an exatecan-based ADC.

Mannheim University of Applied Sciences (MUAS) is a modern university with a 125-year-tradition. CeMOS – Research and Transfer Center, the largest research center at Universities of Applied Sciences in Germany, is an important part of MUAS. CeMOS focuses on offering innovative solutions for industry and academia. It operates leading laboratories for mass spectrometry (imaging), mass spectrometry-based compound screening, biomarker discovery, 4D microscopy, 3D cell cultures and 3D bioprinting. The industry consortium M²Aind, led by CeMOS, manages multiple industry projects involving innovative digital technologies for the health industry. Since 2017, M2Aind has been collaborating with 32 partner companies from various areas of the pharmaceutical and chemical industries, biotechnology, medical technology and information technology. The aim of the consortium is to support development of safe and effective drugs and of their production in a resource-efficient and CO2-neutral processes with a focus on digital solutions and multimodal analytics. For this purpose, M2Aind works on high-tech solutions and develops technology platforms in areas such as chemical process development, 3D cell models, spatial metabolomics, cell-based phenotyping, data integration/-analysis and bioprocess control using Machine Learning and process modelling. The combination of experts and an excellent IT infrastructure make M2Aind a unique partner for the health industry.

Intavis Peptide Services has about 30 years of experience in peptide synthesis. As part of Intavis Instruments, initially, peptides were synthesized exclusively for the validation of analytical instruments. With the growing success of peptide drugs, Intavis also expanded and now offers custom peptide synthesis, peptide libraries, and peptide arrays for R&D. In addition, Intavis is currently establishing its GMP production and filling capacities and will offer an end-to-end solution for clinical trials from 2025: from the active pharmaceutical ingredient to the finished medical product. To date, Intavis has contributed to many research projects and formed partnerships with global companies, with Intavis peptides being used in vaccine development and personalized cancer therapy, among other applications. Intavis combines practical experience, scientific expertise, and dedicated employees into a unique service offering. The experienced leadership team has decades of experience in biotechnology and biosciences, and the partner network supports with their knowledge and contacts. Through reliability, effectiveness, and customer orientation, Intavis has earned an excellent reputation in the field of custom peptide synthesis.

KyooBe Tech focuses on the development and commercialization of innovative production technologies for biopharmaceuticals, combining state-of-the-art robotics, automation and biotechnological expertise to create sustainable and integrated process solutions. The key areas of activity involve pathogen inactivation and the automated production of personalized cell and gene therapies. KyooBe Tech has a strong affiliation with Bausch+Ströbel SE + Co. KG, a globally trusted partner for supply in Fill&Finish. eFIT, the first product line entering the market in 2024, aims to inactivate pathogens with low-energy electron irradiation. The main applications are vaccine production, virus depletion in process media, and irradiation of cells in cell therapy production. Since 2022, KyooBe Tech has successfully been operating a test platform to optimize the process parameters for individual applications. KyooBe Tech’s MOSAIC system is designed to address the commercialization challenges of personalized cell therapy production. It offers a novel manufacturing approach that uses separate aseptic boxes for simultaneous batch production. This design particularly supports scale-out strategies, reducing production costs and increasing efficiency. By improving the manufacturing process, MOSAIC helps bridging the gap between early clinical trials and large-scale production, facilitating broader market access and commercial viability.

KnowledgeAgent is a leading specialist for market intelligence. Our areas of expertise include business research, strategic analysis & studies, data analytics and integrated market intelligence solutions. We utilize a broad range of primary and secondary sources to support our customers in all market intelligence-related questions. Our offering covers the life sciences sector along the entire value chain – from (pre-)clinical development through product approval to the production and distribution of medications, medical devices or digital solutions. We primarily work with companies in the fields of biotechnology, pharmaceuticals, CRO/CDMO, medical technology, and financial investors with a focus on life sciences. KnowledgeAgent is a trusted partner of global strategy and management consultants, multinational corporations and mid-market companies. We have been supplying companies and organizations with bespoke intelligence solutions for over 20 years.

We connect companies, research and clinics. The Mannheim Medical Technology Cluster brings together all parties involved in the healthcare industry with the aim of smoothing the way for good ideas to enter the market. To that end, we connect companies of all sizes with clinics and research facilities. The Mannheim Medical Technology Cluster was set up as part of the 2011 Economic and Structural Development Plan and currently comprises around 300 players.

PEPperPRINT is the leading provider of high-density peptide microarrays and related antibody and protein services. From pre-designed off-the-shelf peptide microarrays, to customized contract research solutions, PEPperPRINT offers a wide range of products and services for a variety of research applications. Based on its proprietary laser-printing technology, PEPperPRINT can synthesize tens of thousands of peptides directly on the chip with a unique flexibility in terms of custom peptide content, a high spot density, and reduced material consumption. The product and service portfolio was recently complemented by T cell epitope mapping and monitoring, making PEPperPRINT a one-stop solution provider for the fingerprint analysis of immune responses e.g. for epitope mapping, antibody biomarker discovery or the analysis of adverse immune effects. PEPperPRINT’s peptide microarrays and screening services have been used by researchers around the world with over 250 peer-reviewed publications.

With a portfolio of more than 4,000 products covering the fields of genomics, protein analysis and expression, cellular analysis, drug discovery and genetic identity, Promega is a global leader in providing innovative solutions and technical support to life scientists in academic, industrial and government settings. Promega products are used by life scientists who are asking fundamental questions about biological processes as well as by scientists who are applying scientific knowledge to diagnose and treat diseases, discover new therapeutics, and use genetics and DNA testing for human identification. Since its founding in 1978, Promega has consistently integrated the values of corporate responsibility and sustainable business practices into all aspects of its corporate culture and activity. Promega realizes that its success depends upon the connections the company forges among its customers, community and employees. Since 1997 and with about 100 employees, Promega GmbH, as a subsidiary of the Promega Corp. is responsible for the distribution of Promega products in Germany, Austria, Poland and Eastern Europe.

Quality Assistance is a leading European Contract Research Organisation providing the pharmaceutical industry with all the analytical services required by EMA and FDA regulations for the development and marketing of innovative human medicinal products. The company holds a unique place on the market with all of its laboratories on one site, 250 highly-qualified professionals and more than 40 years’ expertise at the forefront of analytical sciences. They assist their clients from candidate selection, through non-clinical and clinical studies, to marketing authorisation, using our state-of-the-art, product-dedicated expertise in analytical sciences. For each customer and each project, they design customised solutions, define analytical protocols, develop and validate specific new analytical methods and perform characterisation, stability, pharmacokinetic, biomarker and immunogenicity studies as well as batch release testing, in order to evaluate the Quality, Safety and Efficacy of the given drugs.

Recherche und Beratung, Henrik Schreiber is a professional information search service in the area of patents, design, trademarks and literature. Recherche und Beratung is a team of Information Professionals with deep knowledge in chemistry, life sciences, technology and patents. The company’s service includes novelty, state of the art, opposition and freedom to operate searches. Also alerts on competitors or topics can be performed on a regular basis. In the area of chemistry and life sciences chemical structure searches and biosequence searches are offered in addition to keyword / classification searches. Recherche und Beratung, Henrik Schreiber was founded in 2005 and is located in the center of Heidelberg.

Screening Hub is a deep learning-based platform for a wide range of cell screening applications. The modular structure allows a high degree of adaptability to different technical tasks and specific medical fields

Founding is a great thing! Everyone improves our world a little bit in their own way. In doing so, you need full attention for your innovation. But especially during the growth phase, questions like the following often get in your way: What’s happening with my insurance when I’m self-employed? Who can help with my questions all about social insurance? What do I need to consider when hiring new employees? My employees demand benefits, but I have no budget for that, what should I do? We have the right answer to all of these questions, of course tailored to your individual situation!

TRANS DUODENAL CONCEPT developed and manufactures an endoscopic implant to simulate a bypass and to treat diabetes Typ 2, Obesity and fatty liver diseases. Conservative therapies (dietary advice, medication) have only a very limited effect on their own. In between, there is a large gap in care that could affect up to 1 billion people in the future, depending on the indication. The transduodenal barrier (TD barrier) implements the principle of action of surgical bypass surgery with a reversible endoscopic procedure. It is inserted into the gastric outlet and the upper small intestine as part of an outpatient gastroscopy with a “sleeping injection” and removed again after 6-12 months. The TD-Barrier is the patented property of TDC GmbH. In contrast to competitors (not yet available on the market), the balloon-reinforced implant combines the two main mechanisms of bariatric surgery (restriction and malabsorption) by endoscopic means, is therefore similarly effective but reversible and is characterized by unique, atraumatic fixation and high tolerability.

VectorBuilder is a revolutionary platform that provides researchers with one-stop solutions for all their vector design, custom cloning and virus packaging needs. VectorBuilder also offers many other molecular biology services such as stable cell line generation, library construction, BAC modification (recombineering), mutagenesis, and more. The easy to use web-based platform, VectorBuilder.com, serves as both a design tool and ordering portal, allowing researchers from around the globe to design and order construction of their custom vectors and viruses in a matter of minutes. Furthermore, our expansive database of components allows us to minimize gene synthesis thereby decreasing cost and turnaround time. The combination of VectorBuilder’s intuitive interface, extensive experience and competitive prices has helped us become a favorite among academic and industry leaders with thousands of custom vectors and viruses already delivered. Remember, vectors are just complex reagents, so let VectorBuilder work on developing these while you focus on the more important downstream experiments, theory generation and data analysis steps.

WuXi Biologics is a leading contract research, development and manufacturing organization (CRDMO) that provides end-to-end capabilities to healthcare organizations worldwide. With operations in the United States, Ireland, Germany, Singapore and China, they enable their partners to effectively and efficiently bring biologics and vaccines to patients through their comprehensive and high-quality drug development model. WuXi Biologics are currently conducting for their clients and partners (as of December 31, 2023) a total of 698 integrated projects, including 339 in pre-clinical development; 284 in early-phase (phase I and II) clinical development; 51 in late-phase (phase III) development; and 24 in commercial manufacturing. With a total estimated capacity of 580,000 L for biopharmaceutical production planned after 2026, WuXi Biologics provides its clients a robust and premier-quality global supply chain network. Their single-source technology platforms cover a range of biotherapeutics and vaccines produced from either microbial fermentation or mammalian cell culture including monoclonal and bispecific antibodies, ADCs, fusion proteins and other recombinant protein therapeutics and viral-based vaccines. They offer 6 discovery platforms, complete in-house CMC development capabilities and over 262,000 L of single-use bioreactor capacity using their “scale-out” manufacturing paradigm. Multiple drug product facilities support clinical and commercial product fills for liquid or lyophilized formulations in vials, and pre-filled syringes.

YUMAB develops fully human antibodies from target to lead for clients and partners worldwide. Its proprietary antibody platform covers all technologies from antibody discovery – using one of the world’s largest, natural human antibody library collection (>10e11) or customized, patient-derived or immune libraries – to antibody engineering and lead optimization. YUMAB antibodies contain natural, close to germ-line sequences promising low immunogenicity and toxicity. The advanced in vitro and on-cell selection technologies pre-design antibody properties, such as interspecies X-reactivity and developability, early in the development process and provide high success-rates to all types of antigens, including difficult targets like GPCRs or ion channels. Bioinformatic optimization and in vitro evolution technologies provide a direct path towards optimized lead candidates for all antibody drug formats such as full-length IgG, Fab, scFv, bispecifics, CARs, fusion proteins and ADCs.